Livzon Pharmaceutical Group Inc. (HKG:1513)
Hong Kong
· Delayed Price · Currency is HKD 31.18
+0.26 (0.84%)
At close: Dec 5, 2025
HKG:1513 Revenue
Livzon Pharmaceutical Group had revenue of 2.84B CNY in the quarter ending September 30, 2025, with 1.60% growth. This brings the company's revenue in the last twelve months to 11.85B, down -0.09% year-over-year. In the year 2024, Livzon Pharmaceutical Group had annual revenue of 11.81B, down -4.97%.
Revenue (ttm)
11.85B CNY
Revenue Growth
-0.09%
P/S Ratio
2.51
Revenue / Employee
1.31M CNY
Employees
9,067
Market Cap
32.52B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.81B | -617.70M | -4.97% |
| Dec 31, 2023 | 12.43B | -199.54M | -1.58% |
| Dec 31, 2022 | 12.63B | 565.72M | 4.69% |
| Jan 1, 2022 | 12.06B | 1.54B | 14.67% |
| Jan 1, 2021 | 10.52B | 1.14B | 12.10% |
| Jan 1, 2020 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Jan 1, 2018 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 38.69B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| WuXi Biologics | 21.98B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |